Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 17/20 | 0.76 |
| ▸ | MAOB | P27338 | 17/20 | 0.76 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | RXRG | P48443 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501723 | 0.86 | MAOB (1.00) | MAOAMAOBNPC1RAB9A | |
| SCHEMBL30067289 | 0.86 | MAOB (1.00) | MAOAMAOBNPC1RAB9A | |
| SCHEMBL6309072 | 0.84 | MAOB (1.00) | MAOAMAOB | |
| SCHEMBL7215662 | 0.83 | MAOB (0.94) | MAOAMAOBNPC1RAB9A | |
| SCHEMBL7222729 | 0.82 | MAOB (0.97) | MAOAMAOB | |
| SCHEMBL7218099 | 0.80 | MAOB (0.82) | MAOAMAOBNPC1RAB9A | |
| SCHEMBL8462058 | 0.80 | RXRB (0.61) | MAOAMAOBRXRARXRBRXRG | |
| SCHEMBL7566856 | 0.79 | MAOB (0.77) | MAOAMAOB | |
| SCHEMBL6308414 | 0.78 | MAOB (0.82) | MAOAMAOB | |
| SCHEMBL2524800 | 0.77 | MAOB (0.84) | MAOAMAOBNPC1RAB9AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0941112-B1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS | VERTEX PHARMA (US) | 2003-02-12 | — | — | EP | disclosed |
| EP-0839143-B1 | TETRALIN COMPOUNDS WITH MDR ACTIVITY | VERTEX PHARMA (US) | 2002-08-07 | — | — | EP | disclosed |
| US-5811434-A | ADMINISTERING A COMPOSITION COMPRISING A NEUROTROPHIC AMOUNT OF A COMPOUND AND A NEUROTROPHIC FACTOR, SUCH AS NERVE GROWTH FACTOR | VERTEX PHARMACUETICALS INCORPORATED (US) | 1998-09-22 | — | — | US | disclosed |
| US-5726184-A | TREATMENT OF MULTI-DRUG RESISTANT CELLS TO RESTORE SENSITIVITY TO THERAPEUTIC OR PROPHYLACTIC AGENTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-03-10 | — | — | US | disclosed |